RT Journal Article
SR Electronic
T1 Survival Following Diagnosis of HIV-Associated Kaposi Sarcoma Among Adults in East Africa in the “Treat-All” Era
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.26.24312536
DO 10.1101/2024.08.26.24312536
A1 Byakwaga, Helen
A1 Semeere, Aggrey
A1 Laker-Oketta, Miriam
A1 Busakhala, Naftali
A1 Freeman, Esther
A1 Rotich, Elyne
A1 Wenger, Megan
A1 Kadama-Makanga, Philippa
A1 Kisuya, Job
A1 Semakadde, Matthew
A1 Mwine, Bronia
A1 Kasozi, Charles
A1 Mwebesa, Bwana
A1 Maurer, Toby
A1 Glidden, David V.
A1 Kaloustian, Kara Wools-
A1 Kambugu, Andrew
A1 Martin, Jeffrey
YR 2024
UL http://medrxiv.org/content/early/2024/08/28/2024.08.26.24312536.abstract
AB Background Despite widespread access to antiretroviral therapy (ART) in the “Treat All” era, HIV-associated Kaposi sarcoma (KS) remains among the most common malignancies in sub-Saharan Africa. Survival after KS diagnosis has historically been poor in Africa, but knowledge whether survival has changed at the population level in the contemporary era has been limited by lack of community-representative surveillance and monitoring systems.Methods We identified all adult persons living with HIV (PLWH) with a new diagnosis of KS made between 2016 and 2019 during outpatient or inpatient care at prototypical primary care-providing medical facilities in Kenya and Uganda using rapid case ascertainment. Participants were subsequently followed for vital status, including community tracking for those who became lost to follow-up.Findings Among 411 participants with newly diagnosed KS, 71% were men, median age was 34 (IQR: 30 to 41) years, and 91% had ACTG T1 tumor extent. Over a median follow-up of 7.8 (IQR: 2.4 to 17.9) months, cumulative incidence of death (95% CI) at months 6, 12 and 18 were 34% (30% to 39%), 41% (36% to 46%) and 45% (40% to 51%), respectively. Having the highest number of anatomic sites (11 to 16) harboring KS lesions (hazard ratio 2.2 (95% CI: 1.3-3.8) compared to 1 to 3 sites) and presence of oral KS lesions (hazard ratio 2.2 (95% CI: 1.4-3.3)) were independently associated with higher mortality. Lower hemoglobin and CD4 count as well as higher plasma HIV RNA were also associated with higher mortality.Interpretation Among PLWH with newly diagnosed KS in East Africa in the “Treat All” era, survival was poor and related to mucocutaneous extent of KS. The findings emphasize the need for better control of KS in Africa, including novel approaches for earlier detection, better linkage to oncologic care, and more potent therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Institute of Allergy and Infectious Diseases, the National Cancer Institute, and Fogarty International Center, in accordance with the regulatory requirements of the National Institutes of Health under Award Numbers U01AI069911, U54 CA190153, P30 AI027763, U54 CA25457, P30 CA082103 and K43 TW011987.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Research Ethics Committee at Moi University gave ethical approval of this work. Makerere University College of Health Sciences School of Biomedical Sciences Higher Degrees Research and Ethics Committee gave ethical approval of this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors